151 related articles for article (PubMed ID: 20977406)
1. Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V).
Biggar P; Ketteler M
Expert Opin Pharmacother; 2010 Nov; 11(16):2739-50. PubMed ID: 20977406
[TBL] [Abstract][Full Text] [Related]
2. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
Pai AB; Shepler BM
Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
[TBL] [Abstract][Full Text] [Related]
3. Sevelamer carbonate.
Barna MM; Kapoian T; O'Mara NB
Ann Pharmacother; 2010 Jan; 44(1):127-34. PubMed ID: 19955298
[TBL] [Abstract][Full Text] [Related]
4. Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia?
Senatore M; Coppolino G; Papalia T; Greco R; Lofaro D; Bonofiglio R
Eur Rev Med Pharmacol Sci; 2011 Nov; 15(11):1352-4. PubMed ID: 22195373
[No Abstract] [Full Text] [Related]
5. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
Koizumi M; Fukagawa M
Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
[TBL] [Abstract][Full Text] [Related]
6. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
[TBL] [Abstract][Full Text] [Related]
7. Nonphosphate-binding effects of sevelamer--are they of clinical relevance?
Marangon N; Lindholm B; Stenvinkel P
Semin Dial; 2008; 21(5):385-9. PubMed ID: 18573137
[TBL] [Abstract][Full Text] [Related]
8. Sevelamer 'carbonate': what's in a name?
Harland C; Wrong O
Nephrol Dial Transplant; 2010 Apr; 25(4):1354-5. PubMed ID: 20118068
[No Abstract] [Full Text] [Related]
9. Economic evaluation of sevelamer in patients with end-stage renal disease.
Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
[TBL] [Abstract][Full Text] [Related]
10. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
Negri AL
J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
[TBL] [Abstract][Full Text] [Related]
11. [The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease].
Runowski D; Jachimiak B; Cieślak-Puchalska A; Pacanowska B; Zimoń T
Pol Merkur Lekarski; 2009 Apr; 26(154):318-21. PubMed ID: 19580197
[TBL] [Abstract][Full Text] [Related]
12. Sevelamer is cost-saving vs. calcium carbonate in non-dialysis-dependent CKD patients in italy: a patient-level cost-effectiveness analysis of the INDEPENDENT study.
Ruggeri M; Cipriani F; Bellasi A; Russo D; Di Iorio B
Blood Purif; 2014; 37(4):316-24. PubMed ID: 25171148
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
[TBL] [Abstract][Full Text] [Related]
14. Sevelamer reduces the efficacy of many other drugs.
Prescrire Int; 2009 Aug; 18(102):164-5. PubMed ID: 19743578
[TBL] [Abstract][Full Text] [Related]
15. Ten-year experience with sevelamer and calcium salts as phosphate binders.
Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
[TBL] [Abstract][Full Text] [Related]
16. [Management of hyperphosphatemia ; phosphate-binder].
Yokoyama K
Clin Calcium; 2009 Feb; 19(2):205-12. PubMed ID: 19182360
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
[TBL] [Abstract][Full Text] [Related]
18. Oral phosphate binders in patients with kidney failure.
Tonelli M; Pannu N; Manns B
N Engl J Med; 2010 Apr; 362(14):1312-24. PubMed ID: 20375408
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.
Park H; Rascati KL; Keith MS; Hodgkins P; Smyth M; Goldsmith D; Akehurst R
Value Health; 2011 Dec; 14(8):1002-9. PubMed ID: 22152168
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom.
Thompson M; Bartko-Winters S; Bernard L; Fenton A; Hutchison C; Di Iorio B
J Med Econ; 2013; 16(6):744-55. PubMed ID: 23550810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
